View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
June 17, 2021

LoA Update: Aclaris’ topical JAK inhibitor in moderate-to-severe atopic dermatitis approval likelihood soars by 22 points after topline Phase IIa data announcement

Aclaris Therapeutics’ ATI-1777 Likelihood of Approval (LoA) in moderate-to-severe atopic dermatitis rose by 22 points to 47% after positive topline results were revealed from a Phase IIa trial on 8 June.

By Reynald Castañeda

Aclaris Therapeutics’ ATI-1777 Likelihood of Approval (LoA) in moderate-to-severe atopic dermatitis rose by 22 points to 47% after positive topline results were revealed from a Phase IIa trial on 8 June. The asset’s LoA was previously 25%, which was updated on 11 June. The LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm.

In the 50-patient Phase IIa trial, participants were divided into two groups: one receiving topical ATI-1777 JAK 1/3 inhibitor and the other group placed into the vehicle arm. In the primary endpoint modified Eczema Area and Severity Index (mEASI) score at week 4, ATI-1777 demonstrated statistically significant result versus the comparator arm. Final Phase IIa results will be submitted in a peer-reviewed scientific journal for publication, as per the 8 June media release.

Aclaris indicated it is planning to advance ATI-1777 to the next stage of development in in moderate-to-severe atopic dermatitis. The topical’s Phase Transition Success Rate (PTSR) also jumped by 23 points to 50%. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. The LoA is calculated by compounding the PTSR at each stage the drug is yet to progress through.

Aclaris has a $1.07bn market cap.

Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena